Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alkermes plc
AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication
AstraZeneca had hoped data from Phase III PROpel would lead to an all-comers indication in first-line, metastatic castration-resistant prostate cancer, but new indication is limited to BRCA mutations.
AstraZeneca’s IBD Hopes Deflated Amid Evolving Market And Pipeline Competition
The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.
Janssen 340B Discount Growth Slowed In 2022 But Still Topped $6bn; Patient Assistance Jumps 24%
Janssen continues to pursue aggressive policies to reduce inappropriate use of 340B discounts. Firm estimates that 58% of list prices went to commercial and government insurers, 340B providers and others in the US health care system in the form of price concessions last year.
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.
- Other Names / Subsidiaries
- Rodin Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.